No matches
Rhinology

ADVENT On Air | Back Again: Predicting Recurrence in Chronic Rhinosinusitis with Nasal Polyps

Learn from Drs. Bucheit and Wagenmann as they discuss key patient traits that predict disease recurrence in CRSwNP.
Martin Wagenmann
MD, PhD
Martin Wagenmann

Related resources

IRS-ISIAN 2024 | Remission in CRSwNP: A Real-World Perspective

IRS-ISIAN 2024 | Remission in CRSwNP: A Real-World Perspective

expert video
ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future

ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future

expert video
ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

expert video
IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

expert video
IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP

IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP

expert video
IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation

IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation

expert video
ADVENT On Air | Loss of Smell in CRSwNP Patients

ADVENT On Air | Loss of Smell in CRSwNP Patients

Podcast
ADVENT On Air | Remission in CRSwNP

ADVENT On Air | Remission in CRSwNP

Podcast
EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission

expert video
EAACI 2024 Evolving Perspectives in CRSwNP Patient Care

EAACI 2024 Evolving Perspectives in CRSwNP Patient Care

expert video
How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

expert video
Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?

Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?

expert video
Dr. Giorgio Canonica Regarding Multidisciplinary Approach

Dr. Giorgio Canonica Regarding Multidisciplinary Approach

expert video
Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?

Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?

expert video
Connecting Type 2 Inflammation to CRSwNP

Connecting Type 2 Inflammation to CRSwNP

expert video
IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP

IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP

expert video
IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission

IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission

expert video
IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP

IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP

expert video
IRS-ISIAN 2024 | The Importance of Understanding Smell Loss and Congestion in CRSwNP

IRS-ISIAN 2024 | The Importance of Understanding Smell Loss and Congestion in CRSwNP

expert video
CRSwNP: A Chronic Type 2 Inflammatory Disease

CRSwNP: A Chronic Type 2 Inflammatory Disease

expert video
What proportion of patients can achieve control in CRSwNP?

What proportion of patients can achieve control in CRSwNP?

expert video
Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?

expert video
What contributes more to loss of smell in patients with CRSwNP: nasal obstruction or inflammation?

What contributes more to loss of smell in patients with CRSwNP: nasal obstruction or inflammation?

expert video
When is the right time to consider a biologic in patients with CRSwNP?

When is the right time to consider a biologic in patients with CRSwNP?

expert video
How often do you suggest to assess sense of smell?

How often do you suggest to assess sense of smell?

expert video
How does a decrease in smell affect sleep disturbance? Is there any direct relation?

How does a decrease in smell affect sleep disturbance? Is there any direct relation?

expert video
What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?

What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?

expert video
Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

expert video
EAACI 2024 On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control

EAACI 2024 On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control

expert video
Loss of Smell is a Key Symptom of CRSwNP

Loss of Smell is a Key Symptom of CRSwNP

interactivity
Partnering With Patients: Scores That Matter in CRSwNP

Partnering With Patients: Scores That Matter in CRSwNP

interactivity
CRSwNP Triathlon: An Interactive Learning Experience

CRSwNP Triathlon: An Interactive Learning Experience

interactivity
ERS-ISIAN 2025 | Disease Control in CRSwNP

ERS-ISIAN 2025 | Disease Control in CRSwNP

expert video
ERS-ISIAN 2025 | Type 2 Inflammation: Links with Severe/Uncontrolled CRSwNP

ERS-ISIAN 2025 | Type 2 Inflammation: Links with Severe/Uncontrolled CRSwNP

expert video
ERS-ISIAN 2025 | Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions

ERS-ISIAN 2025 | Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions

expert video
ERS-ISIAN 2025 | Treatable Traits in CRSwNP

ERS-ISIAN 2025 | Treatable Traits in CRSwNP

expert video
AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners

AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners

videoanimation
2025 ADVENT Forum | Potential for Disease Modification in the Airway

2025 ADVENT Forum | Potential for Disease Modification in the Airway

expert video
Compounded Burden of Co-existing Type 2 Airway Diseases

Compounded Burden of Co-existing Type 2 Airway Diseases

expert video
Spotlight on Type 2 Inflammation in the Upper and Lower Airways

Spotlight on Type 2 Inflammation in the Upper and Lower Airways

expert video
CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma

CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma

expert video
CRSwNP Interactive Patient Case Tool

CRSwNP Interactive Patient Case Tool

interactivity
The Burden in Patients with CRSwNP and Coexisting Asthma

The Burden in Patients with CRSwNP and Coexisting Asthma

expert video
Type 2 Inflammation: Links With Severe Uncontrolled CRSwNP

Type 2 Inflammation: Links With Severe Uncontrolled CRSwNP

expert video
Head-to-Head Trials of Biologics in CRSwNP

Head-to-Head Trials of Biologics in CRSwNP

expert video
Indirect Treatment Comparison of Biologics Approved for CRSwNP

Indirect Treatment Comparison of Biologics Approved for CRSwNP

expert video

Learning objectives

  • Highlight the rates of disease recurrence for patients with CRSwNP
  • Discuss clinically relevant predictors of disease recurrence in CRSwNP, such as phenotype, endotype, and treatment history, to determine which patients may benefit from surgery versus those who may benefit from another treatment option

Description

Dr. Katie Bucheit and Dr. Martin Wagenmann discuss the incidence of polyp and symptom recurrence for patients with CRSwNP and clinically important patient traits predicting disease recurrence.

Tags
diagnosissymptomsmultiple disease dimensionsdisease progressionmultidisciplinary careexpert insightscoexisting diseases
MAT-GLB-2600215 - 1.0 - 01/2026

About this expert

Rhinology

Martin Wagenmann

MD, PhD

Head of Rhinology, Allergy, and Endoscopic Skull Base Surgery and Head of the Research Laboratory in the ENT Department | University Hospital of Düsseldorf, Germany

See author’s profile
Martin Wagenmann

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ArgentinaChange country/region